Clinical trial
B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency
NCT00024934 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00024934 |
|---|---|
| Title | B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency |
| Official title | A Phase I Dose Escalation Study of B-Lymphocyte Stimulator (BLyS) Administered Subcutaneously in Patients With Selective IgA Deficiency |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | IgA Deficiency |
| Intervention type | Drug |
| Interventions | B-Lymphocyte Stimulator (BLyS) |
| Enrollment | 20 |
| Start date | Oct 1, 2001 |
| Completion | Aug 1, 2004 |
| First posted | Oct 10, 2001 |
| Last update posted | Sep 22, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: